Phase II Trial of Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Feb 2017
At a glance
- Drugs Everolimus (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 06 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Apr 2017.
- 06 Feb 2017 Status changed from completed to active, no longer recruiting.